

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
27 December 2018 (27.12.2018)



(10) International Publication Number
WO 2018/237157 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 31/495 (2006.01)
A61K 39/40 (2006.01) A61K 39/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2018/038775

(22) International Filing Date:

21 June 2018 (21.06.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/523,481 22 June 2017 (22.06.2017) US
62/636,510 28 February 2018 (28.02.2018) US

(71) Applicants: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). **SURFACE ONCOLOGY, INC.** [—/US]; 50 Hampshire Street, 8th Floor, Cambridge, MA 02139 (US).

(72) Inventors: **BROCK, Ansgar**; 10847 Caminito Alto, San Diego, CA 92121 (US). **CREMASCO, Viviana**; 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **SABATOS-PEYTON, Catherine, Anne**; 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **DRANOFF, Glenn**; 150 Concord Road, Sudbury, MA 01776 (US). **PRINZ, Bianka**; Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US). **THOMAS, Jerry, M.**; Adimab, LLC, 7 Lucent Drive, Lebanon, NH 03766 (US). **CHAPEL, Scott**; Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139 (US). **LAKE, Andrew**; Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139 (US). **PATERSON, Alison**; Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139 (US). **O'CONNOR, Rachel, W.**; Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139 (US). **WARREN, Michael**; Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139 (US). **HOLLAND, Pamela**; Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139 (US). **SUBRAMANIAN, Kulandayan, Kasi**; 250 Massachusetts Avenue, Cambridge, MA 02139 (US). **FJAELLSKOG, Marie-Louise**; 48 School Street, Lexington, MA 02421 (US). **BUSSIÈRE, Dirksen**; Emeryville Site 5300 Chiron Way, Bldg. #4, Emeryville, CA 94608 (US). **WOLDEGIORGIS, Mikias**; Emeryville Site 5300 Chiron Way, Bldg. #4, Emeryville, CA 94608 (US). **SHU, Wei**; Emeryville Site 5300 Chiron Way, Bldg. #4, Emeryville, CA 94608 (US). **VENABLE III, John, Delmas**; Novartis Institute for Functional Genomics, Inc., 10675 John Jay Hopkins Drive, San Diego, CA 92121 (US). **GLADS-**

TONE, Michael; Surface Oncology, Inc., 50 Hampshire Street, Cambridge, MA 02139 (US).

(74) Agent: **COLLAZO, Diana, M.** et al.; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODY MOLECULES TO CD73 AND USES THEREOF

(57) Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.

WO 2018/237157 A1